A phase II clinical trial has opened to investigate the safety and effectiveness of the drug belzutifan for pancreatic neuroendocrine tumors (pNETs) and pheochromocytoma/paraganglioma (PPGL).
Etay Ziv, MD, PhD, an interventional radiologist at Memorial Sloan Kettering Cancer Center in New York, leads a translational research study, funded by NETRF through the American Association for Cancer Research, that aims to understand the process of how pancreatic NETs progress from low grade to higher, more aggressive grade tumors.
Doctors at University of California San Francisco (UCSF) are conducting the first-of-its-kind e-NET study to learn about symptoms and quality of life for patients with neuroendocrine cancer. This is your chance to become a citizen scientist and help the researchers learn more about NETs.
The American Association for Cancer Research recently recognized the NETRF-funded research of Ali Azhdarinia, PhD, of the University of Texas Health Science Center at Houston. Dr. Azhdarinia is investigating image-guided precision medicine to treat NETs in the gastrointestinal tract and pancreas that are resistant to chemotherapy.
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to welcome Dr. Matthew H. Kulke and Dr. Daniel M. Halperin to its Board of Scientific Advisors (BOSA), a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the understanding, diagnosis, and treatment of neuroendocrine cancer. Although these renowned physicians may be new to the BOSA, they are not new to NETs or NETRF. In fact, they are both recognized as leading experts worldwide for their care of NET patients and research.
If you could ask Brandon Raabe what a perfect day would look like, he would probably describe a Sunday afternoon in a brewery surrounded by
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to collaborate with the International Neuroendocrine Cancer Alliance (INCA) to share the results from the Survey of